PRESS RELEASE published on 02/10/2025 at 22:00, 9 months 23 days ago Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development Revenues Financial Results 2024 Fiscal Year Inventiva Lanifibranor
BRIEF published on 01/24/2025 at 22:05, 10 months 12 days ago Bilan semestriel du contrat de liquidité d'Inventiva avec Kepler Cheuvreux Contrat De Liquidité Kepler Cheuvreux Biopharmaceutique Transactions Boursières Inventiva
BRIEF published on 01/24/2025 at 22:05, 10 months 12 days ago Half-yearly report on Inventiva's liquidity contract with Kepler Cheuvreux Liquidity Contract Kepler Cheuvreux Biopharmaceutical Stock Market Transactions Inventiva
PRESS RELEASE published on 01/24/2025 at 22:00, 10 months 12 days ago Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Inventiva publie son bilan semestriel du contrat de liquidité avec Kepler Cheuvreux. Espèces de 349 630,55 € et 113 452 actions Inventiva au 31/12/2024. Analyse des transactions du semestre. Entreprise biopharmaceutique axée sur la stéatohépatite et autres maladies Contrat De Liquidité Bilan Semestriel Kepler Cheuvreux Biopharmaceutique Inventiva
PRESS RELEASE published on 01/24/2025 at 22:00, 10 months 12 days ago Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Inventiva announces half-year liquidity contract review with Kepler Cheuvreux. Cash and shares available in the liquidity account disclosed. Company focuses on developing oral small molecule therapies for MASH and unmet medical needs Liquidity Contract Kepler Cheuvreux Clinical-Stage Biopharmaceutical Inventiva MASH
BRIEF published on 01/22/2025 at 22:05, 10 months 14 days ago Inventiva's LEGEND Trial Results to be Presented at EASL SLD Summit 2025 Lanifibranor Empagliflozin LEGEND Trial MASH Treatment EASL Summit 2025
BRIEF published on 01/22/2025 at 22:05, 10 months 14 days ago Les résultats de l'essai LEGEND d'Inventiva seront présentés au sommet EASL SLD 2025 Lanifibranor Empagliflozine Essai De LEGEND Traitement MASH Sommet EASL 2025
PRESS RELEASE published on 01/22/2025 at 22:00, 10 months 14 days ago Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 Inventiva announces selection of LEGEND trial results evaluating lanifibranor and empagliflozin for oral presentation at EASL SLD Summit 2025, showing positive outcomes in MASH patients with T2D Inventiva MASH Lanifibranor Empagliflozin LEGEND Trial
PRESS RELEASE published on 01/22/2025 at 22:00, 10 months 14 days ago Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025 Les résultats de LEGEND sur la combinaison de lanifibranor avec empagliflozine pour la MASH seront présentés au EASL SLD Summit 2025. Améliorations métaboliques et sécurité démontrées MASH Lanifibranor Empagliflozine LEGEND EASL SLD Summit
BRIEF published on 12/17/2024 at 22:05, 11 months 19 days ago Inventiva présente à la J.P. Morgan Healthcare Conference Investisseurs Inventiva NASH Lanifibranor J.P. Morgan Healthcare
Published on 12/06/2025 at 02:00, 1 hour 25 minutes ago Northern Dynasty Provides Update on Board Search and Audit & Risk Committee Composition
Published on 12/06/2025 at 01:15, 2 hours 10 minutes ago Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 3 hours ago GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 3 hours 25 minutes ago Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 3 hours 55 minutes ago 55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 22:15, 5 hours 9 minutes ago CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 5 hours 13 minutes ago EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 8 hours 27 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 9 hours 10 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 23:00, 4 hours 25 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 4 hours 25 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 4 hours 25 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 4 hours 25 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 10 hours 7 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible